Download MendeleyDiscovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2.
Corbett, J.W., Freeman-Cook, K.D., Elliott, R., Vajdos, F., Rajamohan, F., Kohls, D., Marr, E., Zhang, H., Tong, L., Tu, M., Murdande, S., Doran, S.D., Houser, J.A., Song, W., Jones, C.J., Coffey, S.B., Buzon, L., Minich, M.L., Dirico, K.J., Tapley, S., McPherson, R.K., Sugarman, E., Harwood, H.J., Esler, W.(2010) Bioorg Med Chem Lett 20: 2383-2388
- PubMed: 20219367
- DOI: https://doi.org/10.1016/j.bmcl.2009.04.091
- Primary Citation of Related Structures:
3H0J, 3H0Q, 3H0S - PubMed Abstract:
Screening Pfizer's compound library resulted in the identification of weak acetyl-CoA carboxylase inhibitors, from which were obtained rACC1 CT-domain co-crystal structures. Utilizing HTS hits and structure-based drug discovery, a more rigid inhibitor was designed and led to the discovery of sub-micromolar, spirochromanone non-specific ACC inhibitors. Low nanomolar, non-specific ACC-isozyme inhibitors that exhibited good rat pharmacokinetics were obtained from this chemotype.
Organizational Affiliation:
Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA. jmc1983mac@gmail.com
